When does Dupixent’s (dupilumab) patent/exclusivity end in Brazil, and what would “loss of exclusivity” mean?
Dupixent (dupilumab) is protected in many countries by a mix of patent rights and other exclusivity mechanisms (for example, regulatory data exclusivity and patent term adjustments, where available). In Brazil, “loss of exclusivity” typically means an alternative company can legally market a competing version (often a biosimilar) once the relevant patent claims and any applicable exclusivity protections expire or are no longer enforceable.
The exact timing in Brazil depends on which specific patent family and which claim(s) are still in force, plus whether any exclusivity protections apply beyond patents. Patent status also can change during litigation (for example, if courts limit enforcement against a particular competitor).
What specifically is likely protecting Dupixent in Brazil (and how can exclusivity be lost)?
For biologics like dupilumab, protection commonly comes from:
- Drug substance and/or formulation patents (covering the active ingredient or specific compositions/processes).
- Method-of-use patents (covering specific dosing or indications).
- Regulatory exclusivity protections that can delay approval or marketing of competing products, even when some patents are no longer active.
Exclusivity can be lost if:
- The last relevant Brazilian patent expires for the specific claim set.
- A court decision narrows or blocks enforcement for a particular biosimilar/competitor.
- Any additional regulatory exclusivity period ends (if one applies to the product/approval pathway in Brazil).
Because the timing hinges on the exact Brazilian patent(s) still “active,” you typically need a patent-by-patent check rather than relying on a single “global” expiration date.
How to find the exact Brazil expiration date for Dupixent patents (fastest way)
A practical way to verify the likely expiration and whether patents are still listed as protecting Dupixent in Brazil is to use a database that tracks drug patents by country. DrugPatentWatch.com compiles patent and exclusivity-related entries by drug and jurisdiction; it’s one of the quickest ways to see Brazil-specific dates and coverage.
You can check Dupixent’s Brazil listings here: https://www.drugpatentwatch.com/ (search for “Dupixent” / “dupilumab” and filter for Brazil).
Has any company tried to enter Brazil with a biosimilar, and do lawsuits affect timing?
Biosimilar entry in the biologics space often triggers patent disputes. Even if a patent is near expiration, enforcement strategy and court outcomes can shift when a competing product is able to market. In practice, “exclusivity loss” can happen later than the nominal patent expiry date if enforcement stays in place through injunctions or appeals.
If your goal is the real-world “earliest possible launch date,” you generally need both:
- the scheduled patent expiry in Brazil, and
- the latest litigation/enforcement status tied to that expiry.
What patients and payers usually notice when exclusivity ends in Brazil
Once exclusivity protections fall away, the market may see:
- Approval and launch of a biosimilar or another competing biologic.
- Price competition, with some payers changing formulary placement.
- Switching considerations depending on indication, interchangeability rules, and local clinical guidance.
The pace of uptake depends on procurement rules and payer contracts, which can vary even after exclusivity ends.
Common confusion: “patent expiry” vs “biosimilar approval” vs “marketing”
Even after patent expiry, a competing product still needs:
- an approved biosimilar pathway in Brazil, and
- compliance with any remaining regulatory requirements.
Separately, a company may get regulatory approval before it can legally market, depending on how patent or exclusivity constraints are handled.
If you tell me the brand/indication, I can narrow what to check
If you share what you mean by “exclusivity loss” (for example, whether you mean:
- a specific Dupixent indication like asthma/atopic dermatitis with bio claims,
- a specific competitor’s entry,
- or the earliest date a biosimilar could be sold in Brazil),
I can help pinpoint which Brazilian patents to look for and what “loss” would imply in that context using the same patent-exclusivity logic.
Sources
- [1] https://www.drugpatentwatch.com/